Last 7 days
1.2%
Last 30 days
14.6%
Last 90 days
5.5%
Trailing 12 Months
4.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
SYK | 108.0B | 18.4B | 9.81% | 7.15% | 45.81 | 5.86 | 7.84% | 18.25% |
ISRG | 89.4B | 6.2B | 12.38% | -15.32% | 67.62 | 14.37 | 8.97% | -22.43% |
BSX | 71.6B | 12.7B | 6.86% | 12.96% | 102.61 | 5.65 | 6.68% | -32.95% |
BDX | 70.1B | 19.0B | 7.04% | -3.24% | 43.54 | 3.69 | -0.43% | -8.78% |
EW | 50.3B | 5.4B | 3.61% | -29.72% | 33.07 | 9.35 | 2.86% | 1.25% |
MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 14.55% | 4.57% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.6B | 847.1M | 7.86% | 25.46% | -5.3K | 12.54 | 13.32% | -137.89% |
GMED | 5.6B | 1.0B | -2.14% | -23.23% | 32.76 | 5.52 | 6.76% | 24.45% |
IRTC | 3.7B | 410.9M | 4.99% | -21.24% | -32.24 | 9.11 | 27.29% | -14.60% |
TNDM | 2.6B | 801.2M | 10.62% | -65.08% | -27.7 | 3.27 | 14.00% | -707.69% |
SMALL-CAP | ||||||||
ATEC | 1.7B | 350.9M | 3.38% | 35.65% | -10.93 | 4.74 | 44.26% | -5.42% |
SILK | 1.5B | 138.6M | -18.17% | -5.23% | -27.28 | 10.83 | 36.62% | -10.44% |
AVNS | 1.4B | 820.0M | 5.46% | -11.22% | 27.4 | 1.69 | 10.13% | 701.59% |
CSII | 833.4M | 239.8M | 0.46% | -12.12% | -22.01 | 3.47 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 13.9% | 490 | 430 | 364 | 299 | 237 |
Gross Profit | 14.9% | 425 | 370 | 310 | 252 | 196 |
S&GA Expenses | 6.8% | 162 | 152 | 138 | 123 | 111 |
R&D Expenses | 12.4% | 82.00 | 73.00 | 66.00 | 57.00 | 51.00 |
EBITDA | 34.8% | 128 | 95.00 | 61.00 | 34.00 | -4.14 |
EBITDA Margin | 18.3% | 0.26* | 0.22* | 0.17* | 0.11* | -0.02* |
Earnings Before Taxes | 35.4% | 121 | 89.00 | 56.00 | 29.00 | -8.84 |
EBT Margin | 18.9% | 0.25* | 0.21* | 0.15* | 0.10* | -0.04* |
Interest Expenses | 55.5% | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Net Income | 145.4% | 216 | 88.00 | 55.00 | 29.00 | -9.14 |
Net Income Margin | 115.4% | 0.44* | 0.20* | 0.15* | 0.10* | -0.04* |
Free Cahsflow | 33.7% | 93.00 | 69.00 | 48.00 | 23.00 | 3.00 |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 35.8% | 646 | 476 | 417 | 373 | 346 |
Current Assets | 16.2% | 459 | 395 | 352 | 310 | 286 |
Cash Equivalents | 22.5% | 157 | 128 | 100 | 66.00 | 89.00 |
Inventory | 8.9% | 75.00 | 69.00 | 60.00 | 53.00 | 43.00 |
Net PPE | 22.6% | 48.00 | 39.00 | 32.00 | 28.00 | 24.00 |
Liabilities | 12.4% | 135 | 120 | 112 | 105 | 104 |
Current Liabilities | 16.9% | 63.00 | 54.00 | 66.00 | 51.00 | 52.00 |
Long Term Debt | -14.8% | 15.00 | 17.00 | 17.00 | 17.00 | - |
LT Debt, Current | -100.0% | - | 6.00 | - | - | - |
LT Debt, Non Current | 130.6% | 15.00 | 6.00 | 9.00 | 12.00 | - |
Shareholder's Equity | 43.7% | 511 | 356 | 305 | 268 | 242 |
Retained Earnings | 79.3% | -36.81 | -177 | -212 | -238 | -252 |
Additional Paid-In Capital | 2.6% | 549 | 535 | 519 | 507 | 495 |
Accumulated Depreciation | - | 6.00 | - | - | - | - |
Shares Outstanding | NaN% | - | - | 35,826 | 35,587 | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 36.7% | 118 | 86.00 | 61.00 | 34.00 | 15.00 |
Share Based Compensation | 11.0% | 45.00 | 40.00 | 36.00 | 32.00 | 27.00 |
Cashflow From Investing | -24.4% | -62.15 | -49.98 | -49.48 | -28.08 | 26.00 |
Cashflow From Financing | 233.1% | 13.00 | 4.00 | 6.00 | 3.00 | -2.45 |
98.1%
71.5%
61.2%
Y-axis is the maximum loss one would have experienced if Shockwave Medical was unfortunately bought at previous high price.
87.0%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-29 | Diametric Capital, LP | reduced | -25.35 | -773,203 | 952,797 | 0.46% |
2023-03-23 | MetLife Investment Management, LLC | reduced | -1.35 | -3,104,080 | 8,368,530 | 0.07% |
2023-03-17 | American Portfolios Advisors | new | - | 1,161,220 | 1,161,220 | 0.05% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | new | - | 339,051 | 339,051 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -11.8 | -38,153,300 | 71,529,700 | 0.07% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -13.55 | -20,004,200 | 35,448,800 | 0.04% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | new | - | 411,220 | 411,220 | 0.06% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -3.8 | -81,000 | 197,000 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | sold off | -100 | - | - | -% |
2023-02-28 | Voya Investment Management LLC | added | 7.81 | -1,872,040 | 7,357,960 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | price t rowe associates inc /md/ | 2.8% | 1,012,393 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Jan 23, 2023 | blackrock inc. | 12.7% | 4,572,659 | SC 13G/A | |
Jan 10, 2023 | vanguard group inc | 10.22% | 3,694,931 | SC 13G/A | |
Jul 08, 2022 | blackrock inc. | 12.1% | 4,313,553 | SC 13G | |
Feb 14, 2022 | price t rowe associates inc /md/ | 8.7% | 3,077,252 | SC 13G/A | |
Feb 14, 2022 | gilder gagnon howe & co llc | 3.9% | 1,384,358 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 7.7% | 2,716,533 | SC 13G/A | |
Jan 10, 2022 | fmr llc | - | 0 | SC 13G/A | |
Nov 09, 2021 | jpmorgan chase & co | 3.4% | 1,209,265 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 0.03 -99.99% | 0.03 -99.99% | 0.07 -99.97% | 0.11 -99.95% | 0.19 -99.91% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 28, 2023 | 4 | Insider Trading | |
Mar 22, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4/A | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 4 | Insider Trading | |
Feb 27, 2023 | 10-K | Annual Report | |
Feb 27, 2023 | S-8 | Employee Benefits Plan | |
Feb 24, 2023 | 4 | Insider Trading | |
Feb 23, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-27 | Zacharias Isaac | sold | -862,760 | 215 | -4,000 | president, cco |
2023-03-20 | PUCKETT DAN | sold | -220,814 | 200 | -1,100 | chief financial officer |
2023-03-20 | WATKINS FRANK T | acquired | 6,588 | 2.196 | 3,000 | - |
2023-03-20 | PUCKETT DAN | acquired | 18,700 | 17.00 | 1,100 | chief financial officer |
2023-03-20 | WATKINS FRANK T | sold | -602,015 | 200 | -3,000 | - |
2023-03-10 | Zacharias Isaac | sold (taxes) | -102,790 | 190 | -541 | president, cco |
2023-02-27 | Zacharias Isaac | sold | -754,040 | 188 | -4,000 | president, cco |
2023-02-23 | Sainz Maria | sold | -139,732 | 193 | -724 | - |
2023-02-22 | Phung Trinh | sold | -120,378 | 188 | -640 | vp, finance |
2023-02-22 | PUCKETT DAN | sold | -700,244 | 191 | -3,653 | chief financial officer |
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Product revenue | $ 489,733,000 | $ 237,146,000 | $ 67,789,000 |
Cost of revenue: | |||
Cost of product revenue | 64,996,000 | 41,438,000 | 20,991,000 |
Gross profit | 424,737,000 | 195,708,000 | 46,798,000 |
Operating expenses: | |||
Research and development | 81,679,000 | 50,544,000 | 36,926,000 |
Sales and marketing | 161,995,000 | 111,288,000 | 51,672,000 |
General and administrative | 56,929,000 | 34,747,000 | 23,863,000 |
Total operating expenses | 300,603,000 | 196,579,000 | 112,461,000 |
Income (loss) from operations | 124,134,000 | (871,000) | (65,663,000) |
Loss from equity method investment | (2,475,000) | (6,286,000) | 0 |
Interest expense | (1,886,000) | (1,096,000) | (1,212,000) |
Other income (expense), net | 1,055,000 | (582,000) | 1,256,000 |
Net income (loss) before taxes | 120,828,000 | (8,835,000) | (65,619,000) |
Income tax (benefit) provision | (95,168,000) | 301,000 | 80,000 |
Net income (loss) | 215,996,000 | (9,136,000) | (65,699,000) |
Other comprehensive income (loss) | |||
Unrealized loss on available-for-sale securities, net of tax | (659,000) | (211,000) | (5,000) |
Adjustment for net gain realized and included in other income, net | (6,000) | 0 | (21,000) |
Total comprehensive income (loss) | $ 215,331,000 | $ (9,347,000) | $ (65,725,000) |
Net income (loss) per share | |||
Basic (USD per share) | $ 6.02 | $ (0.26) | $ (1.99) |
Diluted (USD per share) | $ 5.70 | $ (0.26) | $ (1.99) |
Denominator: | |||
Basic (in shares) | 35,900,738 | 35,098,130 | 33,088,095 |
Diluted (in shares) | 37,881,590 | 35,098,130 | 33,088,095 |
Revenue, Product and Service [Extensible Enumeration] | Product [Member] | Product [Member] | Product [Member] |
Cost, Product and Service [Extensible Enumeration] | Product [Member] | Product [Member] | Product [Member] |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 156,586 | $ 89,209 |
Short-term investments | 147,907 | 111,772 |
Accounts receivable, net | 71,366 | 37,435 |
Inventory | 75,112 | 42,978 |
Prepaid expenses and other current assets | 8,292 | 4,508 |
Total current assets | 459,263 | 285,902 |
Operating lease right-of-use assets | 32,365 | 27,496 |
Property and equipment, net | 48,152 | 24,361 |
Equity method investment | 3,512 | 5,987 |
Deferred tax assets | 97,568 | 0 |
Other assets | 5,229 | 1,936 |
TOTAL ASSETS | 646,089 | 345,682 |
CURRENT LIABILITIES: | ||
Accounts payable | 6,721 | 3,520 |
Debt, current portion | 0 | 5,500 |
Accrued liabilities | 55,375 | 40,870 |
Lease liability, current portion | 1,278 | 1,738 |
Total current liabilities | 63,374 | 51,628 |
Lease liability, noncurrent portion | 34,928 | 28,321 |
Debt, noncurrent portion | 24,198 | 11,630 |
Related party contract liability, noncurrent portion | 12,273 | 12,273 |
TOTAL LIABILITIES | 134,773 | 103,852 |
Commitments and contingencies (Note 6) | ||
STOCKHOLDERS’ EQUITY: | ||
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; No shares issued and outstanding as of December 31, 2022 and 2021 | 0 | 0 |
Common stock, $0.001 par value per share; 281,274,838 shares authorized; 36,235,546 and 35,444,472 issued and outstanding as of December 31, 2022 and 2021 | 36 | 35 |
Additional paid-in capital | 548,960 | 494,806 |
Accumulated other comprehensive loss | (867) | (202) |
Accumulated deficit | (36,813) | (252,809) |
TOTAL STOCKHOLDERS’ EQUITY | 511,316 | 241,830 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 646,089 | $ 345,682 |